Galmed Pharmaceuticals Ltd. GLMD 深 沪
等待开盘 04-01 09:30:00 美东时间
0.49
+0.015
+3.16%
华盛通- 最 高0.5199
- 今 开0.5199
- 成交量 1.51万股
- 最 低 0.47
- 昨 收 0.475
- 总市值 322.49万
- 52周最高 2.68
- 市盈率 静 --
- 换手率 0.23%
- 52周最低 0.4111
- 委 比 99.80%
- 总股本 658.14万
- 历史最高 4870.80
- 量 比 0.65
- 振 幅 10.51%
- 历史最低 0.4111
- 每 手 1
- 风险率 0.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Galmed Pharmaceuticals Receives Nasdaq Noncompliance Notice, Gets Time Through July 28 To Regain Compliance
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced that the Company
01-31 05:15
Galmed Pharma Granted Patent In South Korea For Aramchol And Rezdiffra Combination Therapy In NASH/MASH And Liver Fibrosis
The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and Trademark Office (USPTO), Europe, Canada and other jurisdictions and will expire in the U.S. in July
2025-12-04 21:36
Galmed Pharmaceuticals Granted New Patent for Combination of Aramchol and Rezdiffra (Resmetirom) for MASH Treatment
Galmed Pharmaceuticals Ltd. has announced the grant of new use patents for the combination of its drug candidate Aramchol with Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for the treatment of MAS...
2025-12-04 21:30
Galmed Issues CEO Letter to Shareholders
TEL AVIV, Israel, Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometa...
2025-12-01 21:30
Galmed Pharmaceuticals Q3 EPS $(0.33) Beats $(0.54) Estimate
Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.54) by 38.89 percent. This is a 85.71 percent increase over losses of $(2.31) per share
2025-11-26 21:34
Galmed Pharmaceuticals Reports Top-Line Results From AM-001 Phase 1 Bioavailability Study, Demonstrating Enhanced Pharmacokinetic Profile Of Aramchol Meglumine Granules
The top-line results showed that bioavailability of Aramchol meglumine 400mg and 200mg granules is considerably greater, higher by 5-fold and 3-fold respectively, that of the Aramchol free acid 300mg tabletsThe new
2025-11-18 21:44
Galmed Pharmaceuticals Q2 EPS $(0.63) Beats $(0.83) Estimate
Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.83) by 24.1 percent. This is a 61.82 percent increase over losses of $(1.65) per share
2025-08-28 21:36
MASH drug developers rise as FDA accepts lenient trial requirement
Drug developers with products targeting a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) traded higher on Wednesday after the U.S. FDA said it has accepted an easy-to-m...
2025-08-28 01:44
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Shares of Palo Alto Networks, Inc. (NASDAQ:PANW) rose sharply in pre-market tra...
2025-08-19 20:01
Galmed Pharmaceuticals Reschedules Shareholder Meeting Due to Lack of Quorum
The latest update is out from Galmed Pharmaceuticals ( ($GLMD) ). On August 14,...
2025-08-15 04:32
